AU2017289886A1 - Engineered parasites for delivering protein to the central nervous system (CNS) - Google Patents

Engineered parasites for delivering protein to the central nervous system (CNS) Download PDF

Info

Publication number
AU2017289886A1
AU2017289886A1 AU2017289886A AU2017289886A AU2017289886A1 AU 2017289886 A1 AU2017289886 A1 AU 2017289886A1 AU 2017289886 A AU2017289886 A AU 2017289886A AU 2017289886 A AU2017289886 A AU 2017289886A AU 2017289886 A1 AU2017289886 A1 AU 2017289886A1
Authority
AU
Australia
Prior art keywords
tgme49
length
chr
toxoplasma
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017289886A
Other languages
English (en)
Inventor
Shahar BRACHA
Oded RECHAVI
Lilach SHEINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Ramot at Tel Aviv University Ltd
Original Assignee
University of Glasgow
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Ramot at Tel Aviv University Ltd filed Critical University of Glasgow
Publication of AU2017289886A1 publication Critical patent/AU2017289886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/05—Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
    • C12Y603/05005—Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017289886A 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (CNS) Abandoned AU2017289886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355898P 2016-06-29 2016-06-29
US62/355,898 2016-06-29
PCT/IL2017/050731 WO2018002938A1 (en) 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (cns)

Publications (1)

Publication Number Publication Date
AU2017289886A1 true AU2017289886A1 (en) 2019-01-24

Family

ID=60786743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017289886A Abandoned AU2017289886A1 (en) 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (CNS)

Country Status (8)

Country Link
US (3) US11260081B2 (enExample)
EP (1) EP3478301A4 (enExample)
JP (3) JP7148415B2 (enExample)
KR (1) KR102513120B1 (enExample)
CN (1) CN109757100A (enExample)
AU (1) AU2017289886A1 (enExample)
CA (1) CA3028334A1 (enExample)
WO (1) WO2018002938A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7148415B2 (ja) * 2016-06-29 2022-10-05 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
BR112020021903A2 (pt) 2018-04-27 2021-03-02 Rocket Pharmaceuticals, Ltd. terapia genética para degeneração do snc
CN109369796A (zh) * 2018-09-27 2019-02-22 华中农业大学 一种检测羊弓形虫IgG抗体的酶联免疫方法
CN110117609B (zh) * 2019-05-20 2023-06-02 安徽农业大学 一种真菌基因敲除双荧光筛选方法
EP3976071A1 (en) * 2019-05-29 2022-04-06 Université de Tours Toxoplasma platform for treating cancer
EP3980059A1 (en) * 2019-06-10 2022-04-13 Infectious Disease Research Institute Methods and compositions of astrovirus replicons
CN115379834A (zh) 2020-03-11 2022-11-22 马萨诸塞眼科耳科诊所 用于nmnat1相关视网膜变性的基因疗法
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
KR102561980B1 (ko) * 2021-03-16 2023-08-01 한양대학교 에리카산학협력단 톡소포자충 gra9 단백질 또는 상기 단백질을 암호화하는 유전자를 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물
CN114524869B (zh) * 2022-01-25 2023-06-09 华中农业大学 弓形虫微线体蛋白MIC17a及其应用
KR102834734B1 (ko) * 2022-04-28 2025-07-16 경희대학교 산학협력단 톡소포자충의 항원 rop4를 포함하는 재조합 백시니아 바이러스 백신
WO2024064918A2 (en) * 2022-09-23 2024-03-28 Novome Biotechnologies, Inc. Recombinant fusion polypeptides for secreting soluble, heterologous cargo
WO2025026988A1 (en) * 2023-07-28 2025-02-06 Theranexus Mutated tfeb for treating lysosomal disorders
EP4560316A1 (en) * 2023-11-23 2025-05-28 Biokit Research & Development S.L.U. Antigenic regions for the detection of anti-toxoplasma gondii igm antibodies
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用
WO2025235741A1 (en) * 2024-05-09 2025-11-13 Grann Pharmaceuticals Inc. Compositions and methods for modulating mecp2 activity
CN119925428B (zh) * 2025-04-07 2025-07-11 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN120424771B (zh) * 2025-07-08 2025-10-17 华中农业大学 弓形虫mic19基因敲除虫株及其构建方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US8293224B2 (en) 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
WO2004026903A2 (en) * 2002-09-20 2004-04-01 Akzo Nobel N.V. Live antenuated parasite vaccine
US9757440B2 (en) 2007-10-29 2017-09-12 Trustees Of Dartmouth College Method for treating cancer with Toxoplasma gondii vaccine
WO2016046321A1 (en) * 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases
JP7148415B2 (ja) 2016-06-29 2022-10-05 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Also Published As

Publication number Publication date
US20220160790A1 (en) 2022-05-26
EP3478301A1 (en) 2019-05-08
CA3028334A1 (en) 2018-01-04
US20200121731A1 (en) 2020-04-23
CN109757100A (zh) 2019-05-14
JP2019525744A (ja) 2019-09-12
KR20190021339A (ko) 2019-03-05
US11260081B2 (en) 2022-03-01
EP3478301A4 (en) 2020-04-22
JP7748681B2 (ja) 2025-10-03
JP2022184996A (ja) 2022-12-13
WO2018002938A1 (en) 2018-01-04
US12070476B2 (en) 2024-08-27
JP7497397B2 (ja) 2024-06-10
JP7148415B2 (ja) 2022-10-05
JP2024112982A (ja) 2024-08-21
US20250057892A1 (en) 2025-02-20
KR102513120B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
AU2020204196B2 (en) Optimal maize loci
AU2020203872B2 (en) Optimal maize loci
AU2020203837B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2021200054B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing yield of plants
AU2020202369B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2020204520B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2016381496B2 (en) Plant traits conferred by isolated polynucleotides and polypeptides
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2017234120B2 (en) Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
KR102880582B1 (ko) 다중화 게놈 편집
AU2023251441A1 (en) RNA containing composition for treatment of tumor diseases
AU2021202753A1 (en) Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
AU2021218142A1 (en) Isolated polynucleotides, polypeptides and methods of using same for increasing abiotic stress tolerance, biomass and yield of plants
AU2021203894A1 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
TW202321448A (zh) 利用重組環狀rna改善蛋白質轉譯的組合物及方法
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
AU2019316556B9 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
JP2003135075A (ja) 新規な全長ｃＤＮＡ
JP2003088388A (ja) 新規な全長ｃＤＮＡ
EP1165784A2 (en) Nucleic acids including open reading frames encoding polypeptides; "orfx"
KR20220004117A (ko) 증가된 저장 안정성을 갖는 프로바이오틱 균주
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application